Survival to hospital discharge higher with use of double sequential external defibrillation compared with standard defibrillation

Risk for progression of kidney disease or death from cardiovascular causes reduced with empagliflozin versus placebo

Rate of myocarditis higher after receipt of mRNA-1273, particularly for younger men (younger than 40 years)

Portion of total diet attributed to ultraprocessed food is increasing

Increase especially pronounced for Black adults and adults with lower educational attainment

Outcomes better for surgical revascularization versus endovascular therapy for those with single segment of great saphenous vein that could be used for surgery

Dose-dependent reductions in systolic blood pressure seen in phase 2 dose-ranging study

In patients with T2DM, hypertriglyceridemia, and low HDL cholesterol levels, the risk for cardiovascular events was not lower with pemafibrate versus placebo

Risk-attributable cardiovascular death rate associated with lead exposure higher in the U.S. than the U.K.; opposite pattern seen between the countries for particulate matter exposure

Increases in BP, heart rate greater; reduction in brachial artery diameter greater; and performance on exercise parameters worse for vapers, smokers compared with controls